Effect of CCL21/CCR7 chemokine axis on cell growth
CCL21/CCR7 chemokine axis can affect cell proliferation by mediating different signaling pathways. Early studies have shown that CCL21 can affect the biological activity of hematopoietic progenitor cells by inhibiting their proliferation. Additionally, CCL21/CCR7 chemokine axis can also affect the proliferation of glomerular mesangial cells, CD4+ T cells, CD8+T cells and CD34+cells in bone marrow through different signals (Zhang et al., 2016). It was also proved that CCL21/CCR7 chemokine axis inhibits T cell proliferation by slowing down the degradation of cyclin dependent kinase (CDK) inhibitors and down-regulating the activity of CDK1 (Kuwabara et al., 2012). A recent investigations found that CCL21/CCR7 chemokine axis stimulated the proliferation of DCs in bone marrow through phosphorylating NF-ĸB65. These results provide a new entry point for studying the function of CCL21/CCR7 chemokine axis in terms of proliferation (Korbecki et al., 2020, Li et al., 2020).
Other functions of CCL21/CCR7 chemokine axis
In addition to the above functions, CCL21/CCR7 chemokine axis has a certain effects on cell differentiation, survival, endocytosis, migration rate and invasion ability. Studies have suggestted that the binding of CCL21 and CCR7 can significantly affect the internal structure and migration rate of renal DCs and blood T cells (Luo et al., 2020, Legler et al., 2016). And different concentrations of CCL21 produced different chemotactic rates for renal DCs and blood T cells. The functional diversity of CCL21/CCR7 chemokine axis in the immune process also provides the basis for participating in the occurrence and development of autoimmune diseases. With the continuous in-depth study of CCL21/CCR7 chemokine axis, the role of CCL21/CCR7 chemokine axis has attracted more and more attention from domestic and foreign scholars in autoimmune diseases (Rong et al., 2017, Zlotnik et al., 2012, Sokol et al., 2015).